AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Tresita-M Tablet

Prescription Icon
Prescription Required

Marketer

Pringston Life Sciences

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Tresita-M Tablet

Combiflex-DM is a dual-action tablet managing elevated blood glucose in patients with type 2 diabetes. This aids in preventing serious diabetic complications like renal impairment and vision loss, potentially lessening the risk of cardiovascular events. Combiflex-DM can be used independently or in conjunction with other anti-diabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is personalized based on your health status, glucose levels, and current medications. Consuming it with food minimizes gastrointestinal distress. Consistent daily dosing, at the same time, maximizes efficacy; discontinue only under medical guidance. Adherence to your physician's dietary and exercise plan is crucial for successful diabetes management; lifestyle significantly impacts control. Common side effects include diarrhea, nausea, vomiting, indigestion, headache, and pharyngitis. Hypoglycemia is a potential adverse effect, especially when combined with insulin or sulfonylureas; learn to identify and manage this. Combiflex-DM is not universally suitable. Inform your doctor of any pre-existing kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption before commencing treatment. Pregnant or lactating individuals require medical consultation prior to use. Drug interactions are possible; disclose all medications to your doctor to ensure safety. Alcohol should be limited due to its hypoglycemic effect. Your doctor will monitor kidney function and blood glucose levels throughout treatment.

Primary Ingredients of Tresita-M Tablet

No text was provided to rewrite.

Uses of Tresita-M Tablet

Managing type 2 diabetes

Major Benefits of Tresita-M Tablet:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the Tresita-M Tablet whole; avoid chewing, crushing, or fracturing it. Administer this medication with a meal.

Common Side effects of Tresita-M Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Tresita-M Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the Tresita-M Tablet whole; avoid chewing, crushing, or fracturing it. It should be administered with food.

How Tresita-M Tablet works:

Tresita-M tablets combine sitagliptin and metformin to manage blood sugar. Sitagliptin boosts insulin production by the pancreas, enhances the body's insulin utilization, and diminishes the liver's glucose output. Metformin, a biguanide, reduces hepatic glucose production, slows intestinal glucose absorption, and improves insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol alongside Tresita-M Tablet is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Tresita-M Tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any possible risks prior to prescribing. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Tresita-M Tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by excessively high or low blood sugar levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with impaired kidney function should use Tresita-M Tablets cautiously, potentially requiring dosage modification under medical supervision. Tresita-M Tablets are contraindicated in those with severe kidney disease. Routine monitoring of renal function is recommended during treatment.

LiverLiverUNSAFE

The use of Tresita-M Tablets is likely inadvisable for individuals with hepatic impairment and should be omitted. Medical advice is recommended.

What if you forget to take Tresita-M Tablet :

Should you forget a Tresita-M Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Tresita-M Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Tresita-M Tablet

Tresita-M Tablets combine sitagliptin and metformin to treat type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. Tresita-M is not for use in individuals under 18.
Prolonged Tresita-M Tablet use can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and urinary issues), and cognitive changes (including balance problems). To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Tresita-M Tablet may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use may result in vitamin B12 deficiency.
Tresita-M Tablets are contraindicated in patients with allergies to any ingredient or excipient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Tresita-M Tablet with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label or packaging. Discard any unused medication and ensure it remains inaccessible to children, pets, and others.
Lactic acidosis, a serious medical emergency caused by excess blood lactic acid (also known as Metformin-associated lactic acidosis or MALA), is a potential side effect of Tresita-M Tablets. This rare complication is avoided in patients with kidney disease, the elderly, and heavy alcohol users. Symptoms can include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, stop taking Sitagliptin + Metformin and seek immediate medical attention.
Tresita-M Tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18 years old.
Tresita-M Tablet may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Tresita-M Tablets are contraindicated in patients with hypersensitivity to any ingredient. Avoid use in patients with severe renal or hepatic impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Tresita-M tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency caused by excess blood lactic acid (also known as Metformin-associated lactic acidosis or MALA), is a potential side effect of Tresita-M Tablets. This rare complication is more likely in patients with kidney disease, the elderly, or those who consume excessive alcohol, hence its avoidance in these groups. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. Should these occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Tresita-M Tablet use can induce vitamin B12 deficiency by interfering with its stomach absorption. This deficiency may lead to anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Tresita-M Tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Tresita-M Tablet may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may result in vitamin B12 deficiency.
Tresita-M Tablets are contraindicated in patients with known hypersensitivity to any ingredient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Tresita-M tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA), is a potential side effect of Tresita-M Tablets. This rare complication is more likely in patients with kidney disease, the elderly, or those who consume excessive alcohol, hence its avoidance in such individuals. Symptoms can include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Tresita-M Tablet use can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Tresita-M Tablet
127